The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| 10x Genomics, Inc. | CLASS A COMMON | 88025U109 | 344,598 | 6,837,253 | SH | SOLE | 6,837,253 | 0 | 0 | ||
| Acceleron Pharma Inc. | COM | 00434H108 | 7,452 | 188,602 | SH | SOLE | 188,602 | 0 | 0 | ||
| Aerie Pharmaceuticals, Inc. | COM | 00771V108 | 32,150 | 1,672,714 | SH | SOLE | 1,672,714 | 0 | 0 | ||
| Aimmune Therapeutics, Inc. | COM | 00900T107 | 54,559 | 2,605,499 | SH | SOLE | 2,605,499 | 0 | 0 | ||
| Alder BioPharmaceuticals, Inc. | COM | 014339105 | 2,769 | 146,800 | SH | SOLE | 146,800 | 0 | 0 | ||
| Epizyme, Inc. | COM | 29428V104 | 15,353 | 1,488,444 | SH | SOLE | 1,488,444 | 0 | 0 | ||
| Insmed Incorporated | COM | 457669307 | 16,141 | 915,016 | SH | SOLE | 915,016 | 0 | 0 | ||